ZLAB Earnings Prediction
The chart below shows how ZLAB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ZLAB sees a -5.13% change in stock price 10 days leading up to the earnings, and a -2.59% change 10 days following the report. On the earnings day itself, the stock moves by +0.18%. This data can give you a slight idea of what to expect for the next quarter's release.
ZLAB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
102.27M
47.72%
1.75%
Gross Margin
63.90%
1.11%
-2.65%
Operating Margin
-66.35%
-45.04%
-11.52%
Net Margin
-40.75%
-59.21%
-48.98%
EPS
-0.04
-42.86%
-50.00%
No Data Available
ZLAB Earnings Analysis
Zai Lab Limited American Depositary Shares Corporation (ZLAB.O) Earnings Conference Call
Positive
Q3 Revenue Surge: Total net product revenue for the third quarter grew 47% year-over-year to $101.8 million, driven by increased sales for VYVGART and supported by increased sales for ZEJULA and NUZYRA.
Net Product Revenue Surge: VYVGART net product revenue grew to $27.3 million in the third quarter of 2024 compared to $4.9 million for the same period in 2023, driven by increased sales since its launch in September 2023.
ZEJULA Revenue Increase: ZEJULA net product revenue increased 16% to $48.2 million, remaining strong as it continued to be the leading PARP inhibitor for ovarian cancer in mainland China.
NUZYRA Revenue Surge: NUZYRA net product revenue grew 82% to $10 million, driven by NRDL listings for IV formulation for the treatment of adults with community-acquired bacterial pneumonia or CABP, and acute bacterial skin and skin structure infections or ABSSSI in the first quarter of 2023 and the oral formulation for these indications in the first quarter of 2024.
Net Loss Improvement: Zai Lab reported a net loss of $41.7 million in the third quarter of 2024, improving by 40% year-over-year compared to a net loss of $69.2 million for the same period in 2023.
Negative
Third Quarter Revenue Surge: Total net product revenue for the third quarter was $101.8 million compared to $69.2 million for the same period in 2023, representing a 47% year-over-year growth. This increase was primarily driven by increased sales for VYVGART and also supported by increased sales for ZEJULA and NUZYRA.
R&D Expense Increase: Research and development expenses were $66.0 million in the third quarter of 2024 compared to $58.8 million for the same period in 2023. This increase was primarily due to increased upfront and milestone fees for our license and collaboration agreements, partially offset by decreased clinical trial expenses and personnel cost as a result of ongoing resource prioritization and efficiency efforts.
SG&A Expense Decrease: Selling, general and administrative expenses were $67.2 million in the third quarter of 2024 compared to $68.6 million for the same period in 2023. This decrease was primarily driven by decreased personnel cost as a result of ongoing resource prioritization and efficiency efforts, partially offset by increased general and selling expenses primarily for VYVGART.
Q3 Operating Loss Analysis: Loss from operations in the third quarter of 2024 was $67.9 million, $48.2 million on a non-GAAP basis when adjusted to exclude non-cash expenses including depreciation, amortization and share based compensation, both narrowed by 19% year-over-year.
Net Loss Improvement: Zai Lab reported a net loss of $41.7 million in the third quarter of 2024 or a loss per ordinary share attributable to common shareholders of $0.04, which improved by 40% year-over-year compared to a net loss of $69.2 million for the same period in 2023 or a loss per ordinary share of $0.07.
ZLAB FAQs
How does ZLAB typically perform around its earnings report dates?
Is Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ZLAB Earning Call Sentiment
Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ZLAB.O
-1.97%Positive
The earnings call summary shows strong revenue growth, particularly with VYVGART, and a significant improvement in net loss. The raised guidance for VYVGART and the strategic focus on profitability by 2025 are positive indicators. Despite some risks, such as regulatory challenges and competitive pressures, the overall sentiment is positive. The Q&A section supports this with expectations of continued growth and a favorable competitive landscape for KarXT. The company's market cap suggests a moderate reaction, leading to a prediction of a positive stock price movement of 2% to 8%.
